What is Mounjaro?
Mounjaro® (tirzepatide) is a prescription medication used to support weight loss and improve metabolic health in adults. It is typically prescribed for individuals living with obesity, or those who are overweight with related health conditions.
It is used alongside a reduced-calorie diet and increased physical activity to help patients achieve and maintain weight loss over time.
Mounjaro® works differently from many other treatments by targeting two key hormone pathways involved in appetite and blood sugar regulation (GIP and GLP-1). It should only be used under medical supervision and is not suitable for everyone.
How Mounjaro works in your body
Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. These hormones are naturally released after eating and help regulate appetite, digestion, and insulin response.
By activating both pathways, Mounjaro helps reduce hunger, improve feelings of fullness, and support better control of calorie intake—alongside professional lifestyle advice.
Key mechanisms
Mounjaro works through multiple complementary effects:
- Appetite suppressionMounjaro acts on appetite centres in the brain, helping reduce hunger signals and food cravings. Many users report feeling satisfied with smaller meals and less frequent snacking.
- Slower gastric emptyingIt slows the rate at which food leaves the stomach, helping you feel fuller for longer after eating.
- Improved metabolic controlBy influencing insulin and blood sugar regulation, Mounjaro can support metabolic health, particularly in people with insulin resistance—always within a prescribed care plan.
Journey of Mounjaro in the body
Dual hormone pathways (GIP + GLP-1) — interactive overview (informational only).
Mounjaro timeline: what to expect
Mounjaro is designed to work gradually, with doses increased over time to allow the body to adjust and reduce side effects.
Early changes often include reduced appetite, while more noticeable weight loss develops at higher doses for many people.
Weight loss progression over time
Illustrative chart: percentage change from baseline by month marker (not a personal forecast).
When does Mounjaro start working?
Many users begin to notice reduced appetite within the first few weeks. However, more significant weight loss typically occurs as the dose increases.
Higher doses are associated with stronger and more consistent results for many people, particularly when combined with sustainable lifestyle changes.
Side effects during dose increases
Common side effects may include nausea, diarrhoea or constipation, reduced appetite, and mild gastrointestinal discomfort. These effects are usually temporary and improve as the body adapts.
Follow your prescriber's titration plan; seek urgent advice for severe or persistent symptoms as described in your patient information.
Long-term weight management
Weight loss is a long-term process influenced by biology, behaviour, and environment. Mounjaro supports this process by making it easier to manage appetite and reduce calorie intake.
Clinical evidence shows that the best results occur when medication is combined with healthy eating patterns, regular physical activity, and ongoing behavioural support.
Mounjaro weight loss results (trials)
In large randomised trials of tirzepatide for obesity (e.g. SURMOUNT programme), mean weight change over extended follow-up was substantially greater with active treatment than with placebo, on top of lifestyle intervention. Individual results vary; not everyone responds the same way.
Dosage & treatment plan
Mounjaro is injected once weekly. The dose is usually increased in steps (titration) to improve tolerability. Licensed strengths for weight management in the UK include a stepped range up to a maximum maintenance dose—your prescriber will individualise the plan.
| Dose (weekly) | Typical titration phase |
|---|---|
| 2.5 mg | Starting dose (often month 1) |
| 5 mg | Step-up (often month 2) |
| 7.5 mg | Further step-up |
| 10 mg | Higher step toward maintenance |
| 12.5 mg | Approaching maximum for many |
| 15 mg | Maximum licensed maintenance dose (not universal) |
Always follow the UK SmPC and your prescriber for the pen strength you are issued; titration may be slower if side effects occur.
UK Mounjaro prices at a glance
Preview uses the same data as our comparison hub: a few providers and three pen strengths. The live table adds the full titration grid, monthly hints, and discount mode.
| Provider | Reviews | From | 2.5 mg | 7.5 mg | 15 mg |
|---|---|---|---|---|---|
| Fylde Clinic | 4.8 | £134 | £134 | £210 | £270 |
| Get Weight Loss | 4.4 | £134 | £134 | £208 | £270 |
| Cuva Health | 4.8 | £140 | £140 | £234 | £304 |
25 more providers and the complete strength grid — explore on the comparison page. Open full comparison table | |||||
Prescription-only — a qualified clinician must assess you before supply. Illustrative figures; confirm live checkout prices.
Mounjaro vs other treatments
Quick orientation only—your clinician chooses based on health status, access, and preferences.
| Mounjaro (tirzepatide) | Wegovy (semaglutide) | Saxenda (liraglutide) | |
|---|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist | GLP-1 agonist (daily) |
| Dosing | Once weekly (pen) | Once weekly (pen) | Once daily (pen) |
| Trial weight loss (headline) | Substantial mean loss vs placebo in SURMOUNT programme trials | Substantial mean loss vs placebo at 68 w (STEP-style trials) | Lower mean effect than weekly GLP-1 options in many comparisons |
| Cost (UK private) | Varies by dose and provider; compare monthly all-in costs including consultation and delivery. | ||
| Side effects | GI effects common; rare serious risks exist—seek urgent care for severe abdominal pain or allergic symptoms per patient information. | ||
Side effects & safety
Common adverse effects can include nausea, diarrhoea or constipation, reduced appetite, and mild gastrointestinal discomfort—often worst during titration.
Serious or rare risks in official materials can include pancreatitis, gallbladder disease, and hypersensitivity; contraindications apply. Read your patient information leaflet and seek urgent help if you have severe or persistent symptoms.
Who can use Mounjaro in the UK?
Mounjaro may be prescribed for adults who meet clinical criteria—for example BMI of 30 or higher, or BMI of 27 or higher with weight-related conditions—subject to consultation, exclusions, and SmPC rules. NHS access follows national and local commissioning (see NICE TA1026 and NHS England implementation guidance). Private pathways use their own clinical criteria.
Treatment suitability must always be assessed by a qualified healthcare professional.
How to get Mounjaro in the UK
- NHS — where NICE TA1026 and local commissioning apply; eligibility and waiting times vary.
- Private online clinics & pharmacies — questionnaire and ID checks, then prescribing if appropriate.
- Private face-to-face services — some specialist obesity services offer GLP-1/GIP treatment pathways.
Best Mounjaro providers (UK orientation)
Large UK-facing providers include chains and online pharmacies such as Boots Online Doctor, Superdrug Online Doctor, and Simple Online Pharmacy, among others. The "best" choice depends on price transparency, clinical support, delivery, and maintenance policy—compare using our hubs rather than a single headline price.
Trust & verification
- Only use UK pharmacies regulated by the GPhC or equivalent for supply.
- Expect a proper consultation before any prescription-only medicine.
- Cold-chain products should ship with appropriate packaging—ask if unsure.
- Cross-check the pharmacy’s GPhC registration number on the official register.
FAQ
What is Mounjaro and how does it work?
Mounjaro (tirzepatide) is a prescription injection used for weight management in eligible adults. It activates both GIP and GLP-1 receptors, helping reduce appetite, slow stomach emptying, and support metabolic control alongside diet and exercise. It is not suitable for everyone—only a qualified clinician can decide.
How much does Mounjaro cost in the UK?
Private Mounjaro prices vary by dose and provider. In our illustrative April 2026 sample, headline order prices often rise with strength; always confirm live pricing, consultation fees, and delivery on the pharmacy site before you pay.
How is Mounjaro different from Wegovy?
Wegovy contains semaglutide (a GLP-1 receptor agonist). Mounjaro contains tirzepatide, which targets both GIP and GLP-1 pathways. Dosing schedules, trial data, side-effect profiles, and UK access differ. Compare options with your prescriber and our Wegovy vs Mounjaro hub.
Medically reviewed & editorial standards
This guide is written for general education and price transparency. It is reviewed against reputable UK and international sources. It does not replace a consultation with a prescriber who knows your history.
References
- NHS. Mounjaro (tirzepatide). nhs.uk
- NICE. Tirzepatide for managing overweight and obesity (TA1026). nice.org.uk
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2023.
- MHRA. UK medicines regulation & safety updates. gov.uk
